Stereotactic ablative body radiotherapy (SABR) has a role as definitive therapy in many tumor sites; however, its role in the treatment\nof breast cancer is less well explored. Currently, SABR has been investigated in the neoadjuvant and adjuvant setting with a number\nof ongoing feasibility studies.However, its use comes with a number of radiobiological and technical challenges that require further\nevaluation. We have learned much from other extracranial disease sites such as lung, brain, and spine, where definitive treatment\nwith SABR has shown encouraging outcomes. In women with breast cancer, SABR may eliminate the need for invasive surgery,\nreducing healthcare costs and hospital stays and providing an additional curative option for early-stage disease. This poses the\nfollowing question: is there a role for SABR as a definitive therapy in breast cancer?
Loading....